Key clinical point: A total of 84% of HCC patients had at least one emergency department visit within 12 months of therapy.

Major finding: Patients with HCC experienced an average of 3.2 adverse events over a median of 9 months; the most common was pain (75%), followed by infection (39%). Infection was the most costly adverse event ($50,374), and up to 90% of costs were associated with inpatient admissions.

Study details: The data come from 322 adults with HCC who had 12 months of follow-up data available after treatment with tyrosine kinase inhibitor (TKI) monotherapy; immune checkpoint inhibitor (ICI) monotherapy; or FOLFOX combination therapy.

Disclosures: The study was supported by AstraZeneca and some coauthors are AstraZeneca employees. Lead author Dr. Lal had no financial conflicts to disclose.

Source: Lal LS et al. Cancer Rep. 2021 Sep 7. doi: 10.1002/cnr2.1504.

Key clinical point: A total of 84% of HCC patients had at least one emergency department visit within 12 months of therapy.

Major finding: Patients with HCC experienced an average of 3.2 adverse events over a median of 9 months; the most common was pain (75%), followed by infection (39%). Infection was the most costly adverse event ($50,374), and up to 90% of costs were associated with inpatient admissions.

Study details: The data come from 322 adults with HCC who had 12 months of follow-up data available after treatment with tyrosine kinase inhibitor (TKI) monotherapy; immune checkpoint inhibitor (ICI) monotherapy; or FOLFOX combination therapy.

Disclosures: The study was supported by AstraZeneca and some coauthors are AstraZeneca employees. Lead author Dr. Lal had no financial conflicts to disclose.

Source: Lal LS et al. Cancer Rep. 2021 Sep 7. doi: 10.1002/cnr2.1504.

Key clinical point: A total of 84% of HCC patients had at least one emergency department visit within 12 months of therapy.

Major finding: Patients with HCC experienced an average of 3.2 adverse events over a median of 9 months; the most common was pain (75%), followed by infection (39%). Infection was the most costly adverse event ($50,374), and up to 90% of costs were associated with inpatient admissions.

Study details: The data come from 322 adults with HCC who had 12 months of follow-up data available after treatment with tyrosine kinase inhibitor (TKI) monotherapy; immune checkpoint inhibitor (ICI) monotherapy; or FOLFOX combination therapy.

Disclosures: The study was supported by AstraZeneca and some coauthors are AstraZeneca employees. Lead author Dr. Lal had no financial conflicts to disclose.

Source: Lal LS et al. Cancer Rep. 2021 Sep 7. doi: 10.1002/cnr2.1504.

Key clinical point: Arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib was safe and effective in patients with advanced HCC.

Major finding: At one week after the aTACE plus apatinib procedure, levels of AST and ALT were significantly elevated compared with pre-treatment levels, indicating treatment response (65.84 U/L vs 54.15 U/L and 63.44 U/L vs 51.60 U/L, respectively). Median progression-free survival was 10.2 months, and median overall survival was 23.3 months, with longer survival in patients without portal vein tumor thrombus. 

Study details: The data come from 87 consecutive adults with advanced hepatocellular carcinoma who underwent arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced hepatocellular carcinoma between December 2015 and February 2017.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Li Z et al. Can J Gastroenterol Hepatol. 2021 Aug 19. doi: 10.1155/2021/5565793.

Key clinical point: Arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib was safe and effective in patients with advanced HCC.

Major finding: At one week after the aTACE plus apatinib procedure, levels of AST and ALT were significantly elevated compared with pre-treatment levels, indicating treatment response (65.84 U/L vs 54.15 U/L and 63.44 U/L vs 51.60 U/L, respectively). Median progression-free survival was 10.2 months, and median overall survival was 23.3 months, with longer survival in patients without portal vein tumor thrombus. 

Study details: The data come from 87 consecutive adults with advanced hepatocellular carcinoma who underwent arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced hepatocellular carcinoma between December 2015 and February 2017.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Li Z et al. Can J Gastroenterol Hepatol. 2021 Aug 19. doi: 10.1155/2021/5565793.

Key clinical point: Arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib was safe and effective in patients with advanced HCC.

Major finding: At one week after the aTACE plus apatinib procedure, levels of AST and ALT were significantly elevated compared with pre-treatment levels, indicating treatment response (65.84 U/L vs 54.15 U/L and 63.44 U/L vs 51.60 U/L, respectively). Median progression-free survival was 10.2 months, and median overall survival was 23.3 months, with longer survival in patients without portal vein tumor thrombus. 

Study details: The data come from 87 consecutive adults with advanced hepatocellular carcinoma who underwent arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced hepatocellular carcinoma between December 2015 and February 2017.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Li Z et al. Can J Gastroenterol Hepatol. 2021 Aug 19. doi: 10.1155/2021/5565793.

Key clinical point: Serum Prothrombin Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) and alpha-fetoprotein were significant predictors of hepatocellular carcionoma and death in patients with chronic hepatitis B-related cirrhosis.

Major finding: Alpha-fetoprotein levels greater than 7 ng/mL (hazard ratio [HR]: 2.84, 95% confidence interval [CI]: 1.73–4.67) and PIVKA-II levels greater than 50 mAU/mL at virological remission significantly predicted the development of HCC (hazard ratios 2.84 and 2.46, respectively).

Study details: The data come from 293 adults with chronic hepatitis B-related cirrhosis; after an average follow-up of 78 months, 76 patient developed HCC and 19 died.

Disclosures: The study was supported by the Ministry of Science and Technology, National Taiwan University Hospital, and the Liver Disease Prevention & Treatment Research Foundation, Taiwan. Lead author Dr. Su disclosed research grant from Gilead Sciences, and serving on speaker's bureaus for AbbVie, Bayer, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, and Takeda.

Source: Su T-H et al. J Formos Med Assoc. 2021 Aug 24. doi: 10.1016/j.jfma.2021.08.003.

Key clinical point: Serum Prothrombin Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) and alpha-fetoprotein were significant predictors of hepatocellular carcionoma and death in patients with chronic hepatitis B-related cirrhosis.

Major finding: Alpha-fetoprotein levels greater than 7 ng/mL (hazard ratio [HR]: 2.84, 95% confidence interval [CI]: 1.73–4.67) and PIVKA-II levels greater than 50 mAU/mL at virological remission significantly predicted the development of HCC (hazard ratios 2.84 and 2.46, respectively).

Study details: The data come from 293 adults with chronic hepatitis B-related cirrhosis; after an average follow-up of 78 months, 76 patient developed HCC and 19 died.

Disclosures: The study was supported by the Ministry of Science and Technology, National Taiwan University Hospital, and the Liver Disease Prevention & Treatment Research Foundation, Taiwan. Lead author Dr. Su disclosed research grant from Gilead Sciences, and serving on speaker's bureaus for AbbVie, Bayer, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, and Takeda.

Source: Su T-H et al. J Formos Med Assoc. 2021 Aug 24. doi: 10.1016/j.jfma.2021.08.003.

Key clinical point: Serum Prothrombin Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) and alpha-fetoprotein were significant predictors of hepatocellular carcionoma and death in patients with chronic hepatitis B-related cirrhosis.

Major finding: Alpha-fetoprotein levels greater than 7 ng/mL (hazard ratio [HR]: 2.84, 95% confidence interval [CI]: 1.73–4.67) and PIVKA-II levels greater than 50 mAU/mL at virological remission significantly predicted the development of HCC (hazard ratios 2.84 and 2.46, respectively).

Study details: The data come from 293 adults with chronic hepatitis B-related cirrhosis; after an average follow-up of 78 months, 76 patient developed HCC and 19 died.

Disclosures: The study was supported by the Ministry of Science and Technology, National Taiwan University Hospital, and the Liver Disease Prevention & Treatment Research Foundation, Taiwan. Lead author Dr. Su disclosed research grant from Gilead Sciences, and serving on speaker's bureaus for AbbVie, Bayer, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, and Takeda.

Source: Su T-H et al. J Formos Med Assoc. 2021 Aug 24. doi: 10.1016/j.jfma.2021.08.003.

Key clinical point: After a median of 27 months’ follow-up, the rates of conversion therapy and both overall and progression-free survival were significantly higher in HCC patients treated with pembrolizumab-lenvatinib-TACE compared to those treated with lenvatinib-TACE.

Major finding: The rate of conversion therapy at the last follow-up was 25.7% in the pembrolizumab-lenvatinib-TACE group vs 11.1% in the lenvatinib-TACE group; median overall survival was 18.1 months in the pembrolizumab-lenvatinib-TACE group vs 14.1 months in the lenvatinib-TACE group, and median progression-free survival interval was 9.2 months in the pembrolizumab-lenvatinib-TACE group vs 5.5 months in the lenvatinib-TACE group.

Study details: The data come from a retrospective study of 142 consecutive adult patients with programmed cell death ligand-1 (PD-L1)-positive unresectable hepatocellular carcinoma who were treated with either pembrolizumab-lenvatinib-transarterial chemoembolization (TACE) or lenvatinib-TACE sequential therapy.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Chen S et al. J Cancer Res Clin Oncol. 2021 Aug 28. doi: 10.1007/s00432-021-03767-4.

Key clinical point: After a median of 27 months’ follow-up, the rates of conversion therapy and both overall and progression-free survival were significantly higher in HCC patients treated with pembrolizumab-lenvatinib-TACE compared to those treated with lenvatinib-TACE.

Major finding: The rate of conversion therapy at the last follow-up was 25.7% in the pembrolizumab-lenvatinib-TACE group vs 11.1% in the lenvatinib-TACE group; median overall survival was 18.1 months in the pembrolizumab-lenvatinib-TACE group vs 14.1 months in the lenvatinib-TACE group, and median progression-free survival interval was 9.2 months in the pembrolizumab-lenvatinib-TACE group vs 5.5 months in the lenvatinib-TACE group.

Study details: The data come from a retrospective study of 142 consecutive adult patients with programmed cell death ligand-1 (PD-L1)-positive unresectable hepatocellular carcinoma who were treated with either pembrolizumab-lenvatinib-transarterial chemoembolization (TACE) or lenvatinib-TACE sequential therapy.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Chen S et al. J Cancer Res Clin Oncol. 2021 Aug 28. doi: 10.1007/s00432-021-03767-4.

Key clinical point: After a median of 27 months’ follow-up, the rates of conversion therapy and both overall and progression-free survival were significantly higher in HCC patients treated with pembrolizumab-lenvatinib-TACE compared to those treated with lenvatinib-TACE.

Major finding: The rate of conversion therapy at the last follow-up was 25.7% in the pembrolizumab-lenvatinib-TACE group vs 11.1% in the lenvatinib-TACE group; median overall survival was 18.1 months in the pembrolizumab-lenvatinib-TACE group vs 14.1 months in the lenvatinib-TACE group, and median progression-free survival interval was 9.2 months in the pembrolizumab-lenvatinib-TACE group vs 5.5 months in the lenvatinib-TACE group.

Study details: The data come from a retrospective study of 142 consecutive adult patients with programmed cell death ligand-1 (PD-L1)-positive unresectable hepatocellular carcinoma who were treated with either pembrolizumab-lenvatinib-transarterial chemoembolization (TACE) or lenvatinib-TACE sequential therapy.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Chen S et al. J Cancer Res Clin Oncol. 2021 Aug 28. doi: 10.1007/s00432-021-03767-4.

Key clinical point: The overall rate of uterine perforation after intrauterine device (IUD) insertion was less than 1%, but higher with placement at 4-8 weeks postpartum compared to 9-36 weeks postpartum.

Major finding:  After adjusting for multiple variables, perforation rates associated with IUDs were significantly higher when placed at 4-8 weeks vs. 9-36 weeks postpartum (0.78% versus 0.46%, P = .001). Expulsion rates were low and similar between the early and late placement groups (1.02 vs. 1.17).

Study details: The data come from a retrospective cohort study of 24,959 women who underwent insertion of an intrauterine device at a single center. A total of 430 patients had confirmed complications; 157 of these were uterine perforations and 273 were intrauterine device expulsions.

Disclosures: The study received no outside funding. Lead author Dr. Ramos-Rivera had no financial conflicts to disclose. A coauthor is supported by the NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development.

Source: Ramos-Rivera M et al. Am J Obstet Gynecol. 2021 Aug 27. doi: 10.1016/j.ajog.2021.08.028.

Key clinical point: The overall rate of uterine perforation after intrauterine device (IUD) insertion was less than 1%, but higher with placement at 4-8 weeks postpartum compared to 9-36 weeks postpartum.

Major finding:  After adjusting for multiple variables, perforation rates associated with IUDs were significantly higher when placed at 4-8 weeks vs. 9-36 weeks postpartum (0.78% versus 0.46%, P = .001). Expulsion rates were low and similar between the early and late placement groups (1.02 vs. 1.17).

Study details: The data come from a retrospective cohort study of 24,959 women who underwent insertion of an intrauterine device at a single center. A total of 430 patients had confirmed complications; 157 of these were uterine perforations and 273 were intrauterine device expulsions.

Disclosures: The study received no outside funding. Lead author Dr. Ramos-Rivera had no financial conflicts to disclose. A coauthor is supported by the NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development.

Source: Ramos-Rivera M et al. Am J Obstet Gynecol. 2021 Aug 27. doi: 10.1016/j.ajog.2021.08.028.

Key clinical point: The overall rate of uterine perforation after intrauterine device (IUD) insertion was less than 1%, but higher with placement at 4-8 weeks postpartum compared to 9-36 weeks postpartum.

Major finding:  After adjusting for multiple variables, perforation rates associated with IUDs were significantly higher when placed at 4-8 weeks vs. 9-36 weeks postpartum (0.78% versus 0.46%, P = .001). Expulsion rates were low and similar between the early and late placement groups (1.02 vs. 1.17).

Study details: The data come from a retrospective cohort study of 24,959 women who underwent insertion of an intrauterine device at a single center. A total of 430 patients had confirmed complications; 157 of these were uterine perforations and 273 were intrauterine device expulsions.

Disclosures: The study received no outside funding. Lead author Dr. Ramos-Rivera had no financial conflicts to disclose. A coauthor is supported by the NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development.

Source: Ramos-Rivera M et al. Am J Obstet Gynecol. 2021 Aug 27. doi: 10.1016/j.ajog.2021.08.028.

Key clinical point: No significant associations were noted between contraception choice and age, previous pregnancies, or social determinants of health, but nearly 100% of women opted for some form of contraception following a pregnancy termination.

Major finding:  Prior to pregnancy termination, 58.5% of women reported not using contraception, and 22.4% reported using a barrier or fertility awareness. After pregnancy termination, 99.7% of women chose a form of contraception, and 95.2% chose a more effective method than what they had been using. After 6 months, 85.8% were still using contraception, and 37.8% were still using a more effective method.

Study details: The data come from a cross-sectional study of 400 women who underwent termination of pregnancy over a 2-year period. Information about contraception choice was collected before pregnancy termination, at the time of termination, and at 6 months following termination.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Smith SN et al. J Obstet Gynaecol Can. 2021 Aug 27. doi: 10.1016/j.jogc.2021.07.012.

Key clinical point: No significant associations were noted between contraception choice and age, previous pregnancies, or social determinants of health, but nearly 100% of women opted for some form of contraception following a pregnancy termination.

Major finding:  Prior to pregnancy termination, 58.5% of women reported not using contraception, and 22.4% reported using a barrier or fertility awareness. After pregnancy termination, 99.7% of women chose a form of contraception, and 95.2% chose a more effective method than what they had been using. After 6 months, 85.8% were still using contraception, and 37.8% were still using a more effective method.

Study details: The data come from a cross-sectional study of 400 women who underwent termination of pregnancy over a 2-year period. Information about contraception choice was collected before pregnancy termination, at the time of termination, and at 6 months following termination.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Smith SN et al. J Obstet Gynaecol Can. 2021 Aug 27. doi: 10.1016/j.jogc.2021.07.012.

Key clinical point: No significant associations were noted between contraception choice and age, previous pregnancies, or social determinants of health, but nearly 100% of women opted for some form of contraception following a pregnancy termination.

Major finding:  Prior to pregnancy termination, 58.5% of women reported not using contraception, and 22.4% reported using a barrier or fertility awareness. After pregnancy termination, 99.7% of women chose a form of contraception, and 95.2% chose a more effective method than what they had been using. After 6 months, 85.8% were still using contraception, and 37.8% were still using a more effective method.

Study details: The data come from a cross-sectional study of 400 women who underwent termination of pregnancy over a 2-year period. Information about contraception choice was collected before pregnancy termination, at the time of termination, and at 6 months following termination.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Smith SN et al. J Obstet Gynaecol Can. 2021 Aug 27. doi: 10.1016/j.jogc.2021.07.012.

Key clinical point: In 2019, 41% of health care providers prescribed regular contraception at the same time as emergency contraception; this percentage was an increase from 2013-2014, but falls short of the US Selected Practice Recommendations for Contraceptive Use, first released in 2013.

Major finding:  Health care providers in 2019 were more likely than health care providers in 2013 and 2014 to prescribe or provide contraception when providing emergency contraception (adjusted prevalence ratio 1.26) and to provide a copper intrauterine device (adjusted prevalence ratio 3.87). A total of 41% frequently provided or prescribed regular contraception at the time of providing emergency contraceptive pills (ECP), 16% of providers in 2019 frequently provided an advance prescription for ECPs, 8% provided a copper intrauterine device as emergency contraception, and 7% provided an advance supply of ECPs.

Study details: The data come from two cross-sectional surveys mailed to office-based physicians and public-sector health care providers in the United States in 2013-14 (2,060 respondents) and 2019 (1,420 respondents).

Disclosures: The study was published on behalf of the Jacobs Institute of Women’s Health. The researchers had no financial conflicts to disclose.

Source: Pagano HP et al. Womens Health Issues. 2021 Sep 9. doi: 10.1016/j.whi.2021.07.006.

Key clinical point: In 2019, 41% of health care providers prescribed regular contraception at the same time as emergency contraception; this percentage was an increase from 2013-2014, but falls short of the US Selected Practice Recommendations for Contraceptive Use, first released in 2013.

Major finding:  Health care providers in 2019 were more likely than health care providers in 2013 and 2014 to prescribe or provide contraception when providing emergency contraception (adjusted prevalence ratio 1.26) and to provide a copper intrauterine device (adjusted prevalence ratio 3.87). A total of 41% frequently provided or prescribed regular contraception at the time of providing emergency contraceptive pills (ECP), 16% of providers in 2019 frequently provided an advance prescription for ECPs, 8% provided a copper intrauterine device as emergency contraception, and 7% provided an advance supply of ECPs.

Study details: The data come from two cross-sectional surveys mailed to office-based physicians and public-sector health care providers in the United States in 2013-14 (2,060 respondents) and 2019 (1,420 respondents).

Disclosures: The study was published on behalf of the Jacobs Institute of Women’s Health. The researchers had no financial conflicts to disclose.

Source: Pagano HP et al. Womens Health Issues. 2021 Sep 9. doi: 10.1016/j.whi.2021.07.006.

Key clinical point: In 2019, 41% of health care providers prescribed regular contraception at the same time as emergency contraception; this percentage was an increase from 2013-2014, but falls short of the US Selected Practice Recommendations for Contraceptive Use, first released in 2013.

Major finding:  Health care providers in 2019 were more likely than health care providers in 2013 and 2014 to prescribe or provide contraception when providing emergency contraception (adjusted prevalence ratio 1.26) and to provide a copper intrauterine device (adjusted prevalence ratio 3.87). A total of 41% frequently provided or prescribed regular contraception at the time of providing emergency contraceptive pills (ECP), 16% of providers in 2019 frequently provided an advance prescription for ECPs, 8% provided a copper intrauterine device as emergency contraception, and 7% provided an advance supply of ECPs.

Study details: The data come from two cross-sectional surveys mailed to office-based physicians and public-sector health care providers in the United States in 2013-14 (2,060 respondents) and 2019 (1,420 respondents).

Disclosures: The study was published on behalf of the Jacobs Institute of Women’s Health. The researchers had no financial conflicts to disclose.

Source: Pagano HP et al. Womens Health Issues. 2021 Sep 9. doi: 10.1016/j.whi.2021.07.006.

Key clinical point: Use of progestin-releasing long-acting reversible contraceptives (LARC) was linked to weight gain in nulliparous adolescents aged 14-19 years; 25% of the study population was obese, and significant interaction effect (P = .017) showed a greater increase in BMI in this subset of participants who used an LARC compared to a copper intrauterine device (IUD).

Major finding:  The mean change in body mass index among teen girls who used LARC was an increase of 0.73 kg/m²; BMI increases averaged 0.92 kg/m² for those who used an etornogestrel subdermal implant plus levonorgestrel intrauterine device (LNG-IUD) and 0.37 kg/m² in those who used a copper IUD.

Study details: The data come from a retrospective cohort study of 196 adolescents aged 14-19 years who underwent placement of long-acting reversible contraceptive devices.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Scott N et al. J Pediatr Adolesc Gynecol. 2021 Aug 10. doi: 10.1016/j.jpag.2021.08.004.

Key clinical point: Use of progestin-releasing long-acting reversible contraceptives (LARC) was linked to weight gain in nulliparous adolescents aged 14-19 years; 25% of the study population was obese, and significant interaction effect (P = .017) showed a greater increase in BMI in this subset of participants who used an LARC compared to a copper intrauterine device (IUD).

Major finding:  The mean change in body mass index among teen girls who used LARC was an increase of 0.73 kg/m²; BMI increases averaged 0.92 kg/m² for those who used an etornogestrel subdermal implant plus levonorgestrel intrauterine device (LNG-IUD) and 0.37 kg/m² in those who used a copper IUD.

Study details: The data come from a retrospective cohort study of 196 adolescents aged 14-19 years who underwent placement of long-acting reversible contraceptive devices.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Scott N et al. J Pediatr Adolesc Gynecol. 2021 Aug 10. doi: 10.1016/j.jpag.2021.08.004.

Key clinical point: Use of progestin-releasing long-acting reversible contraceptives (LARC) was linked to weight gain in nulliparous adolescents aged 14-19 years; 25% of the study population was obese, and significant interaction effect (P = .017) showed a greater increase in BMI in this subset of participants who used an LARC compared to a copper intrauterine device (IUD).

Major finding:  The mean change in body mass index among teen girls who used LARC was an increase of 0.73 kg/m²; BMI increases averaged 0.92 kg/m² for those who used an etornogestrel subdermal implant plus levonorgestrel intrauterine device (LNG-IUD) and 0.37 kg/m² in those who used a copper IUD.

Study details: The data come from a retrospective cohort study of 196 adolescents aged 14-19 years who underwent placement of long-acting reversible contraceptive devices.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Scott N et al. J Pediatr Adolesc Gynecol. 2021 Aug 10. doi: 10.1016/j.jpag.2021.08.004.

Key clinical point: A review of 58 YouTube videos on removal of long-acting reversible contraception showed more than 4 million views overall; reasons for removal included negative side effects, fear of side effects, and desire for pregnancy.

Major finding:  Most of the women who created the 58 videos were white (53%), 31% were Black, and 14% were Latina. Of these, 56 of 58 successfully removed their device and described the experience as positive in terms of ease of removal.

Study details: The data come from a review of 58 videos on self-removal of long-acting reversible contraception based on YouTube keyword searches. The videos included 48 individuals removing an intrauterine device and 10 removing an implant.

Disclosures: The study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and by the National Science Foundation Graduate Research Fellowship Program. The researchers had no financial conflicts to disclose.

Source: Broussard K and Becker A. Contraception. 2021 Aug 13. doi: 10.1016/j.contraception.2021.08.002.

Key clinical point: A review of 58 YouTube videos on removal of long-acting reversible contraception showed more than 4 million views overall; reasons for removal included negative side effects, fear of side effects, and desire for pregnancy.

Major finding:  Most of the women who created the 58 videos were white (53%), 31% were Black, and 14% were Latina. Of these, 56 of 58 successfully removed their device and described the experience as positive in terms of ease of removal.

Study details: The data come from a review of 58 videos on self-removal of long-acting reversible contraception based on YouTube keyword searches. The videos included 48 individuals removing an intrauterine device and 10 removing an implant.

Disclosures: The study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and by the National Science Foundation Graduate Research Fellowship Program. The researchers had no financial conflicts to disclose.

Source: Broussard K and Becker A. Contraception. 2021 Aug 13. doi: 10.1016/j.contraception.2021.08.002.

Key clinical point: A review of 58 YouTube videos on removal of long-acting reversible contraception showed more than 4 million views overall; reasons for removal included negative side effects, fear of side effects, and desire for pregnancy.

Major finding:  Most of the women who created the 58 videos were white (53%), 31% were Black, and 14% were Latina. Of these, 56 of 58 successfully removed their device and described the experience as positive in terms of ease of removal.

Study details: The data come from a review of 58 videos on self-removal of long-acting reversible contraception based on YouTube keyword searches. The videos included 48 individuals removing an intrauterine device and 10 removing an implant.

Disclosures: The study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and by the National Science Foundation Graduate Research Fellowship Program. The researchers had no financial conflicts to disclose.

Source: Broussard K and Becker A. Contraception. 2021 Aug 13. doi: 10.1016/j.contraception.2021.08.002.

Key clinical point: Among young women, the average Pregnancy Risk Index (PRI) was 4.75; individuals using teratogenic medication had the lowest PRI (0.32); 88% of these individuals used reversible contraception and 31% used long-acting reversible contraception.

Major finding:  Approximately 73% of sexually active young women received contraceptive counseling, which was associated with a significantly increased use of reversible and dual contraception, but not long-acting reversible contraception. At last reported vaginal sex, 65% reported using condoms, 49% reported using reversible contraception, and 12% reported using long-acting reversible contraception.

Study details: The data come from a cross-sectional survey of 177 hospitalized females aged 14 to 21 years at two academic medical centers; the surveys assessed sexual health behaviors, contraceptive use, contraceptive counseling, and pregnancy complications. Researchers calculated the Pregnancy Risk Index (the number per 100 individuals who will become pregnant in the next year).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Hunt JA et al. Hosp Pediatr. 2021 Sep 13. doi: 10.1542/hpeds.2021-005810.

Key clinical point: Among young women, the average Pregnancy Risk Index (PRI) was 4.75; individuals using teratogenic medication had the lowest PRI (0.32); 88% of these individuals used reversible contraception and 31% used long-acting reversible contraception.

Major finding:  Approximately 73% of sexually active young women received contraceptive counseling, which was associated with a significantly increased use of reversible and dual contraception, but not long-acting reversible contraception. At last reported vaginal sex, 65% reported using condoms, 49% reported using reversible contraception, and 12% reported using long-acting reversible contraception.

Study details: The data come from a cross-sectional survey of 177 hospitalized females aged 14 to 21 years at two academic medical centers; the surveys assessed sexual health behaviors, contraceptive use, contraceptive counseling, and pregnancy complications. Researchers calculated the Pregnancy Risk Index (the number per 100 individuals who will become pregnant in the next year).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Hunt JA et al. Hosp Pediatr. 2021 Sep 13. doi: 10.1542/hpeds.2021-005810.

Key clinical point: Among young women, the average Pregnancy Risk Index (PRI) was 4.75; individuals using teratogenic medication had the lowest PRI (0.32); 88% of these individuals used reversible contraception and 31% used long-acting reversible contraception.

Major finding:  Approximately 73% of sexually active young women received contraceptive counseling, which was associated with a significantly increased use of reversible and dual contraception, but not long-acting reversible contraception. At last reported vaginal sex, 65% reported using condoms, 49% reported using reversible contraception, and 12% reported using long-acting reversible contraception.

Study details: The data come from a cross-sectional survey of 177 hospitalized females aged 14 to 21 years at two academic medical centers; the surveys assessed sexual health behaviors, contraceptive use, contraceptive counseling, and pregnancy complications. Researchers calculated the Pregnancy Risk Index (the number per 100 individuals who will become pregnant in the next year).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Hunt JA et al. Hosp Pediatr. 2021 Sep 13. doi: 10.1542/hpeds.2021-005810.